Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
|Articles|December 1, 2011
Pharmaceutical Technology Europe
- Pharmaceutical Technology Europe-12-01-2011
- Volume 23
- Issue 12
The Development of a Floating Drug-Delivery System for Metronidazole
Author(s)Shamsuddin Sultan Khan, Mesbah Uddin Talukder
The authors developed a metronidazole-based floating drug-delivery system to investigate the effect of rate-controlling polymers on release pattern and duration of buoyancy in matrix tablets.
Advertisement
By Shamsuddin Sultan Khan and Mesbah Uddin Talukder
Sustained-release dosage forms enable prolonged action of a drug in the body. Much research has focused on overcoming the short residence times and unpredictable gastric emptying times of drugs in sustained-release oral drug-delivery systems (1). A floating drug-delivery system floats in the gastric juice without affecting the gastric emptying rate. It forms a cohesive gel barrier that serves as a reservoir and releases the drug over the desired period of time. This technique helps increase a drug's gastric residence time and reduces the variability in bioavailability (2, 3).
This article was also published in our US sister publication Pharmaceutical Technology and can be read
Articles in this issue
almost 15 years ago
Mitigating Personnel Risksalmost 15 years ago
The Impact Of Single-Use Systemsalmost 15 years ago
Contamination: Invisible And Airbornealmost 15 years ago
Contract API Manufacturing: The Year in Reviewalmost 15 years ago
Avoiding Contamination Risks in Aseptic Processesalmost 15 years ago
Choosing Cleanroom Clothingalmost 15 years ago
The Employment Outlook Brightensalmost 15 years ago
It’s déjà vu all over againalmost 15 years ago
Newsalmost 15 years ago
Impact of AgeingAdvertisement
Related to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
Advertisement
Advertisement